- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00246571
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
July 2, 2012 updated by: Pfizer
A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer
The purpose of this study is to compare progression free survival for SU011248 [sutent (sunitinib malate)] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
217
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sofia, Bulgaria, 1233
- Pfizer Investigational Site
-
Sofia, Bulgaria, 1527
- Pfizer Investigational Site
-
Sofia, Bulgaria, 1756
- Pfizer Investigational Site
-
Stara Zagora, Bulgaria, 6000
- Pfizer Investigational Site
-
Varna, Bulgaria, 9000
- Pfizer Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Pfizer Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Pfizer Investigational Site
-
-
-
-
-
Brno, Czech Republic, 656 91
- Pfizer Investigational Site
-
Praha 8, Czech Republic, 180 00
- Pfizer Investigational Site
-
-
Ceska Republika
-
Brno, Ceska Republika, Czech Republic, 656 91
- Pfizer Investigational Site
-
Praha 8, Ceska Republika, Czech Republic, 180 81
- Pfizer Investigational Site
-
-
-
-
-
BESANCON Cedex 5, France, 25052
- Pfizer Investigational Site
-
BESANCON cedex, France, 25030
- Pfizer Investigational Site
-
NANTES cedex, France, 44805
- Pfizer Investigational Site
-
Paris Cedex 20, France, 75970
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Germany, 10177
- Pfizer Investigational Site
-
-
-
-
-
Budapest, Hungary, 1082
- Pfizer Investigational Site
-
Budapest, Hungary, 1122
- Pfizer Investigational Site
-
-
-
-
-
Aviano (PN), Italy, 33081
- Pfizer Investigational Site
-
Milano, Italy, 20100
- Pfizer Investigational Site
-
Prato, FI, Italy, 59100
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spain, 08035
- Pfizer Investigational Site
-
Gerona, Spain, 17007
- Pfizer Investigational Site
-
Lleida, Spain, 25198
- Pfizer Investigational Site
-
Malaga, Spain, 29010
- Pfizer Investigational Site
-
Sevilla, Spain, 41013
- Pfizer Investigational Site
-
-
-
-
Balcali
-
Adana, Balcali, Turkey, 01330
- Pfizer Investigational Site
-
-
Besevler
-
Ankara, Besevler, Turkey, 06510
- Pfizer Investigational Site
-
-
Pendik
-
Istanbul, Pendik, Turkey, 34890
- Pfizer Investigational Site
-
-
Sihhiye
-
Ankara, Sihhiye, Turkey, 06100
- Pfizer Investigational Site
-
-
-
-
-
Dnipropetrovsk, Ukraine, 49102
- Pfizer Investigational Site
-
Kyiv, Ukraine, 03115
- Pfizer Investigational Site
-
Odessa, Ukraine, 65055
- Pfizer Investigational Site
-
-
-
-
-
Edinburgh, United Kingdom, EH4 2XU
- Pfizer Investigational Site
-
Oxfordshire, United Kingdom, OX3 7LJ
- Pfizer Investigational Site
-
Southampton, United Kingdom, SO16 6YD
- Pfizer Investigational Site
-
-
-
-
California
-
Corona, California, United States, 92879
- Pfizer Investigational Site
-
Fullerton, California, United States, 92835
- Pfizer Investigational Site
-
Glendora, California, United States, 91741
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90095-1772
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90095-7423
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90095
- Pfizer Investigational Site
-
Mission Hills, California, United States, 91345
- Pfizer Investigational Site
-
Northridge, California, United States, 91325
- Pfizer Investigational Site
-
Palm Springs, California, United States, 92262-4885
- Pfizer Investigational Site
-
Pasadena, California, United States, 91105
- Pfizer Investigational Site
-
Pomona, California, United States, 91767
- Pfizer Investigational Site
-
Rancho Cucamonga, California, United States, 91730
- Pfizer Investigational Site
-
Santa Monica, California, United States, 90404
- Pfizer Investigational Site
-
Valencia, California, United States, 91355
- Pfizer Investigational Site
-
West Covina, California, United States, 91790
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, United States, 80010
- Pfizer Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Pfizer Investigational Site
-
-
Florida
-
Boca Raton, Florida, United States, 33428
- Pfizer Investigational Site
-
Gainesville, Florida, United States, 32605-4391
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30341
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30342
- Pfizer Investigational Site
-
Decatur, Georgia, United States, 30033
- Pfizer Investigational Site
-
Macon, Georgia, United States, 31217
- Pfizer Investigational Site
-
Marietta, Georgia, United States, 30060
- Pfizer Investigational Site
-
Tucker, Georgia, United States, 30084
- Pfizer Investigational Site
-
-
Illinois
-
Zion, Illinois, United States, 60099
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Pfizer Investigational Site
-
-
Michigan
-
Bloomfield Hills, Michigan, United States, 48302
- Pfizer Investigational Site
-
Brownstown, Michigan, United States, 48183
- Pfizer Investigational Site
-
Dearborn, Michigan, United States, 48126
- Pfizer Investigational Site
-
Detroit, Michigan, United States, 48202
- Pfizer Investigational Site
-
West Bloomfield, Michigan, United States, 48322
- Pfizer Investigational Site
-
-
Mississippi
-
Biloxi, Mississippi, United States, 39532
- Pfizer Investigational Site
-
-
Missouri
-
Clarkson Valley, Missouri, United States, 63011
- Pfizer Investigational Site
-
St. Louis, Missouri, United States, 63141
- Pfizer Investigational Site
-
St. Louis, Missouri, United States, 63109
- Pfizer Investigational Site
-
-
New Jersey
-
Midland Park, New Jersey, United States, 07432
- Pfizer Investigational Site
-
Morristown, New Jersey, United States, 07962
- Pfizer Investigational Site
-
Paramus, New Jersey, United States, 07652
- Pfizer Investigational Site
-
Pompton Plains, New Jersey, United States, 07444
- Pfizer Investigational Site
-
Ridgewood, New Jersey, United States, 07450
- Pfizer Investigational Site
-
Summit, New Jersey, United States, 07902
- Pfizer Investigational Site
-
Westwood, New Jersey, United States, 07675
- Pfizer Investigational Site
-
-
New York
-
Bronx, New York, United States, 10451
- Pfizer Investigational Site
-
Bronx, New York, United States, 10461
- Pfizer Investigational Site
-
-
North Carolina
-
Clinton, North Carolina, United States, 28388
- Pfizer Investigational Site
-
Goldsboro, North Carolina, United States, 27534
- Pfizer Investigational Site
-
Wilson, North Carolina, United States, 27893
- Pfizer Investigational Site
-
-
Oklahoma
-
Del City, Oklahoma, United States, 73115
- Pfizer Investigational Site
-
-
Pennsylvania
-
Greensburg, Pennsylvania, United States, 15601
- Pfizer Investigational Site
-
Hershey, Pennsylvania, United States, 17033-0850
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15213
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15232-1305
- Pfizer Investigational Site
-
Wexford, Pennsylvania, United States, 15090
- Pfizer Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Pfizer Investigational Site
-
Memphis, Tennessee, United States, 38120
- Pfizer Investigational Site
-
Memphis, Tennessee, United States, 38133
- Pfizer Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75230-2510
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75230
- Pfizer Investigational Site
-
Fort Worth, Texas, United States, 76177
- Pfizer Investigational Site
-
Houston, Texas, United States, 77024
- Pfizer Investigational Site
-
Houston, Texas, United States, 77055
- Pfizer Investigational Site
-
Plano, Texas, United States, 75093
- Pfizer Investigational Site
-
Plano, Texas, United States, 75075
- Pfizer Investigational Site
-
Richardson, Texas, United States, 75080
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78229
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78207
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78217
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78258
- Pfizer Investigational Site
-
San Atonio, Texas, United States, 78229
- Pfizer Investigational Site
-
Tyler, Texas, United States, 75702
- Pfizer Investigational Site
-
-
Washington
-
Federal Way, Washington, United States, 98003
- Pfizer Investigational Site
-
Lakewood, Washington, United States, 98499
- Pfizer Investigational Site
-
Puyallup, Washington, United States, 98372
- Pfizer Investigational Site
-
Seattle, Washington, United States, 98104
- Pfizer Investigational Site
-
Seattle, Washington, United States, 98122
- Pfizer Investigational Site
-
Tacoma, Washington, United States, 98405
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Recurrent or metastatic breast cancer
- Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative status
- Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting
- Relapse following adjuvant chemotherapy within 6 months of last treatment and/or received one or two chemotherapy regimens for advanced disease
Exclusion Criteria:
- More than two chemotherapy regimens for advanced disease
- Uncontrolled/symptomatic spread of cancer to the brain
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: B
|
The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.
|
Experimental: A
|
SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily.
1-week treatment rests and dose reductions allowed for dose-limiting toxicity.
Dose escalate SU011248 to 50-mg daily if minimal toxicities .
Study will continue until disease progression.
Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
|
Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause.
PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4.
Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was "Death").
|
Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants With Objective Response
Time Frame: Baseline until response or disease progression (up to 3 years from first dose)
|
Objective response based assessment of confirmed response (CR) or confirmed partial response (PR) according to RECIST.
CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
PR are those with a greater than or equal to (≥) 30% decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD.
|
Baseline until response or disease progression (up to 3 years from first dose)
|
Duration of Response (DR)
Time Frame: Time from first response to disease progression up to 3 years from first dose
|
Time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death.
Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4.
DR was calculated for the subgroup of participants with a confirmed objective tumor response.
|
Time from first response to disease progression up to 3 years from first dose
|
Survival Probability at 1 Year
Time Frame: Baseline until death (up to 3 years after first dose of study medication)
|
Probability that the participants will survive at end of 1 year from the first dose of study treatment.
Calculated using data collected from baseline until death (up to 3 years after first dose of study medication).
Probability calculated from Kaplan-Meier estimate.
|
Baseline until death (up to 3 years after first dose of study medication)
|
Overall Survival (OS)
Time Frame: Baseline until death (up to 3 years after first dose of study medication)
|
Time in months from the date of randomization to date of death due to any cause.
OS was calculated as (date of death minus randomization date plus 1) divided by 30.4.
Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
|
Baseline until death (up to 3 years after first dose of study medication)
|
Health Related Quality of Life (HRQoL) and Disease Related Symptoms as Measured by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire (EORTC-QLQ-C30)
Time Frame: Day 1, Cycle 1; Day 1, odd number cycles; and end of treatment (EOT)/withdrawal
|
EORTC QLQ-C30: global health/QoL, functional domains (physical, role, cognitive, emotional, social), and symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea).
Recall period: past week; response range: not at all to very much; global/QoL range: very poor to excellent.
Scale score range: 0 to 100.
Higher functional/global QoL score = better functioning and higher symptom score = greater degree of symptoms.
|
Day 1, Cycle 1; Day 1, odd number cycles; and end of treatment (EOT)/withdrawal
|
HRQoL and Disease Related Symptoms as Measured by EORTC-QLQ-C30 Breast Cancer Module (BR23) Score
Time Frame: Day 1, Cycle 1; Day 1, odd number cycles; and EOT/withdrawal
|
BR23: measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast.
Recall period: past week; response range: not at all to very much.
Scale score range: 0 to 100.
Higher symptom score = greater degree of symptoms.
|
Day 1, Cycle 1; Day 1, odd number cycles; and EOT/withdrawal
|
Observed Plasma Trough Concentrations (Ctrough) of Sunitinib
Time Frame: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
|
Ctrough of SU012662 (Metabolite of Sunitinib)
Time Frame: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
|
Ctrough of Total Drug (Sunitinib + SU012662)
Time Frame: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
|
Dose-corrected Ctrough of Sunitinib
Time Frame: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Ctrough = plasma concentration of sunitinib prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol.
|
Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Dose-corrected Ctrough of SU012662 (Metabolite of Sunitinib)
Time Frame: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Ctrough = plasma concentration of SU012662 prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol.
|
Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Dose-corrected Ctrough of Total Drug (Sunitinib + SU012662)
Time Frame: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Ctrough = plasma concentration of total drug (Sunitinib + SU012662) prior to study drug administration dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol.
|
Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
|
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2)
Time Frame: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
|
Plasma concentrations of sVEGFR2 were examined as a potential pharmacodynamic marker
|
Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
|
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 3 (sVEGFR3)
Time Frame: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
|
Plasma concentrations of sVEGFR3 were examined as a potential pharmacodynamic marker
|
Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
|
Plasma Concentration of Soluble Vascular Endothelial Growth Factor A (sVEGF-A)
Time Frame: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
|
Plasma concentrations of sVEGF-A were examined as a potential pharmacodynamic marker
|
Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
|
Plasma Concentration of Soluble Placental Growth Factor (sPlGF)
Time Frame: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
|
Plasma concentrations of sPlGF were examined as a potential pharmacodynamic marker
|
Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
|
Plasma Concentration of Soluble Kinase Insert Domain for Tyrosine (sKIT), a Stem Cell Factor Receptor
Time Frame: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
|
Plasma concentrations of sKIT were examined as a potential pharmacodynamic marker
|
Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
|
Circulating Endothelial Cells (CEC)
Time Frame: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
|
Blood samples were collected to enumerate the number of total CECs and sVEGFR1, sVEGFR2 and sVEGFR3 protein expression and/or cellular viability.
|
Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
|
Circulating Tumor Cells (CTC)
Time Frame: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
|
Blood samples were collected to enumerate the number of total CTCs and insulin growth factor 1R positive (IGF-1R+) CTCs
|
Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
May 1, 2010
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
October 27, 2005
First Submitted That Met QC Criteria
October 27, 2005
First Posted (Estimate)
October 30, 2005
Study Record Updates
Last Update Posted (Estimate)
July 12, 2012
Last Update Submitted That Met QC Criteria
July 2, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- A6181077
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteConquer Cancer FoundationRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
Clinical Trials on SU011248
-
PfizerCompletedLiver Neoplasms | Unresectable Hepatocellular CarcinomaKorea, Republic of, Taiwan, France
-
Tony Bekaii-SaabPfizerCompletedEsophageal CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstitutePfizerCompletedPhase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue SarcomaLeiomyosarcoma | Fibrosarcoma | Liposarcoma | Malignant Fibrous HistiocytomaUnited States
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletedPlatinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian TubeGermany
-
Duke UniversityPfizerCompleted
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Completed
-
Sequella, Inc.Completed
-
King Faisal Specialist Hospital & Research CenterCompleted
-
Massachusetts General HospitalDana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...Completed
-
PfizerCompletedBreast NeoplasmsUnited States